In:
Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 28, No. 27 ( 2022-08), p. 2270-2278
Abstract:
N6-methyladenosine (m6A) modification is widespread in eukaryotic mRNA, regulated by m6A demethylase, AlkB homolog 5 (ALKBH5). However, the role of m6A in systemic lupus erythematosus (SLE) is still obscure. We explored ALKBH5 expression in SLE patients and its effects on T cells. Methods: 100 SLE patients and 110 healthy controls were recruited to investigate the expression of ALKBH5 in peripheral blood mononuclear cells (PBMCs). An additional 32 SLE patients and 32 health controls were enrolled to explore the expression of ALKBH5 in T cells. Then we explored the function of ALKBH5 in T cells by lentivirus. Results: The expressions of ALKBH5 were downregulated in both PBMCs and T cells in SLE patients (all P 〈 0.05). In PBMCs: ALKBH5 mRNA levels were associated with complement C4 level in plasma (P 〈 0.05). In T cells: ALKBH5 mRNA levels were downregulated in SLE patients with low complement levels, high anti-dsDNA, anti-Sm, anti-RNP, and proteinuria compared with those without, respectively (all P 〈 0.05); ALKBH5 mRNA levels were negatively related with SLE disease activity index score, erythrocyte sedimentation rate, and anti-dsDNA levels (all P 〈 0.05), and positively correlated with complement C3 and C4 level (all P 〈 0.05). Functionally, the overexpression of ALKBH5 promoted apoptosis and inhibited the proliferation of T cells (all P 〈 0.05). Conclusion: Conclusion: ALKBH5 expression is downregulated in SLE patients and could affect the apoptosis and proliferation of T cells, but the exact mechanism still needs to be further explored.
Type of Medium:
Online Resource
ISSN:
1381-6128
DOI:
10.2174/1381612828666220617154204
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2022
SSG:
15,3
